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Abstract
Background: Haematopoietic stem cells undergo mobilization from bone marrow to blood in response to
physiological stimuli such as ischemia and tissue injury. The aim of study was to determine the kinetics of
circulating CD34+ and CD133+CD34+ progenitor cells in response to 75 g glucose load in subjects with normal and
impaired glucose metabolism.
Methods: Asian Indian male subjects (n = 50) with no prior history of glucose imbalance were subjected to 2 hour
oral glucose tolerance test (OGTT). 24 subjects had normal glucose tolerance (NGT), 17 subjects had impaired
glucose tolerance (IGT) and 9 had impaired fasting glucose (IFG). The IGT and IFG subjects were grouped together
as pre-diabetes group (n = 26). Progenitor cell counts in peripheral circulation at fasting and 2 hour post glucose
challenge were measured using direct two-color flow cytometry.
Results: The pre-diabetes group was more insulin resistant (p < 0.0001) as measured by homeostasis assessment
model (HOMA-IR) compared to NGT group. A 2.5-fold increase in CD34+ cells (p = 0.003) and CD133+CD34+ (p =
0.019) cells was seen 2 hours post glucose challenge in the NGT group. This increase for both the cell types was
attenuated in subjects with IGT. CD34+ cell counts in response to glucose challenge inversely correlated with
neutrophil counts (r = -0.330, p = 0.019), while post load counts of CD133+CD34+ cells inversely correlated with
serum creatinine (r = -0.312, p = 0.023).
Conclusion: There is a 2.5-fold increase in the circulating levels of haematopoietic stem cells in response to
glucose challenge in healthy Asian Indian male subjects which is attenuated in subjects with pre-diabetes.
Background
Haematopoietic stem cell (HSCs) characterized by sur-
face expression of CD34, or CD133 or both exhibit
extreme plasticity. Upon receipt of physiological stimuli
these cells mobilize from bone marrow into peripheral
circulation to mediate multi-lineage engraftment of
organs of even non-haematopoietic origin such as skele-
tal muscle, central nervous system, heart and liver [1].
This pool of immature stem cells is capable of giving
rise to progenitors of the cardiovascular system such as
the endothelial progenitor cells (EPCs), cardiomyocytes
and smooth muscle cell progenitors [2]. They follow cir-
cadian kinetics [3] and get mobilized in response to
ischemia imparted by acute myocardial infarction (MI)
[4]. Similarly during menstrual cycle EPCs follow rhyth-
mic oscillations with maximal increase during ovulatory
stage [5].
Abnormalities in carbohydrate metabolism form
a continuum which progressively worsens as a subject
transitions from NGT to IGT and from IGT to diabetes.
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This progressive decline in carbohydrate metabolism
parallels a concomitant decrease in vascular health and
circulating bone marrow-derived vascular progenitor
cells [6-11]. Both type 1- and type 2- diabetes are asso-
ciated with significant reduction in circulating levels of
CD34+ cells and EPCs [7,9-13]. Similarly a reduction in
the circulating levels of EPCs is seen in IGT subjects
[9,14]. However all these studies have looked at progeni-
tor cell counts following overnight fasting and till date
no information is available on kinetics of progenitor
cells in response to glucose load. Thus the aims of this
study were to determine 1) whether levels of CD34+,
CD133+ and CD133+CD34+ progenitor cells increase in
circulation in response to glucose load and if it does
then 2) is the increase in progenitor counts altered in
pre-diabetes subjects exhibiting early stages of compro-
mised carbohydrate metabolism. The interest to better
define the relationship between glucose load and pro-
genitor kinetics, also stems from the observation that
post-prandial glucose peaks are strongly correlated with
increased cardiovascular risks [15,16].
Methods
Study Subjects
The study was approved by IIT Madras Institutional
ethics committee in accordance with Declaration of Hel-
sinki as revised in 2000 and as required by the Indian
Council of Medical Research. Asian Indian male subjects
undergoing their first metabolic examination with no
prior history of glucose imbalance were recruited at Dr.
Mohan’s Diabetes Specialties Centre, a tertiary diabetes
centre in Chennai, India. The following exclusion criteria
were applied: diabetes, established CAD or CVD, smok-
ing, acute infections or immunological disorders, cancer
and recent surgery in the past 10 months. Following
over-night fast, blood was drawn for quantification of cir-
culating progenitor cells and for determination of their
lipid, glucose, insulin and protein profiles. This was fol-
lowed by 75 g OGTT test and blood was redrawn at 2
hours post glucose load for measurement of progenitor
cells, glucose and insulin profiles.
Definitions and diagnostic criteria
NGT were defined as fasting plasma glucose (FPG) <5.5
mmol/l and 2 hour post load glucose <7.8 mmol/l as per
WHO criteria [17]. Pre-diabetes group consisted of sub-
jects with IGT, IFG and combined IGT/IFG. IGT was
defined as 2 hour post-load plasma glucose ≥7.8 mmol/l
and <11.1 mmol/l as per WHO criteria. IFG was defined
based on ADA criteria [17] as FPG ≥5.5 mmol/l and
<7 mmol/l and using WHO criteria as FPG ≥ 6.1 mmol/l
and <7 mmol/l. Among the total subjects recruited
24 were NGT, 17 were IGT and 9 subjects were IFG.
Anthropometric measurements
For all subjects the following parameters were recorded:
age, body mass index (BMI), height, weight, waist to hip
ratio (WHR) and blood pressure. BMI was calculated as
weight in kilograms divided by height expressed in
meters square. Blood pressure was measured in a sitting
position for the right arm to the nearest mm of Hg
using mercury sphygmomanometer (Diamond Deluxe;
Pune, India). Two readings were taken with a 5 minute
interval and the mean of the two was expressed as
blood pressure.
Biochemical parameters
Plasma glucose by glucose oxidase-peroxidase method,
serum cholesterol by cholesterol oxidase-peroxidase-4-
aminophenazone method, serum triglycerides by glycerol
phosphate oxidase peroxidase-4-aminophenazone method
and HDL cholesterol via direct method (with polyethylene
glycol-pretreated enzymes) were measured using the Hita-
chi-912 Autoanalyzer (Hitachi, Manheim, Germany). The
intra- and inter-assay coefficient of variation (%CV) for
these biochemical tests ranged between 3.1% and 7.6%
respectively. LDL cholesterol values were derived using
Friedewald formula. Insulin concentrations were estimated
by enzyme-linked immunosorbent assay (Dako, Glostrup,
Denmark). The intra- and inter-assay %CV for insulin
measurements were 5.7% and 8.9% respectively. HbA1c
was measured by high-pressure liquid chromatography
using the variant machine (BioRad, Hercules, California,
USA). The intra- and inter-assay %CV of HbA1c measure-
ments was less than 10%. Insulin resistance was estimated
using homeostasis assessment model of insulin resistance
(HOMA-IR) calculated as fasting insulin (μU/ml) X fasting
glucose (mmol/l) divided by 22.5.
Quantification of circulating progenitor cells via Flow
Cytometry
Peripheral blood progenitor cells were analyzed for sur-
face expression of CD34 and CD133 through direct
two-color flow cytometry. Peripheral blood was drawn
each at fasting and 2 hr post-load conditions in EDTA
vacutainers (BD Biosciences, USA). Prior to staining,
samples were blocked with 5% fetal bovine serum and
FcR reagent for 20 min. Samples were stained with
CD133-PE and CD34-FITC antibodies (Miltenyi Biotech,
Germany). Corresponding isotype control IgG1-PE and
IgG2a-FITC (Miltenyi Biotech, Germany) antibodies
were used. Following red cell lysis, a minimum of 5 lakh
events were acquired and scored as per EUROSTAR
guidelines [18] using FACS Calibur Flow cytometer
(Becton Dickinson, USA). Data were processed using
Flowjo software program (Version 7.6.1, Tree Star Inc.,
USA). The instrument was daily optimized by analyzing
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the expression of peripheral blood leukocytes with anti-
CD4 and anti-CD3 antibodies. The operator who
acquired the FACS data was masked to the clinical sta-
tus of the subjects. Following appropriate gating, CD34+,
CD133+ and CD133+CD34+ cells were enumerated from
the lympho-monocyte fraction and cell numbers are
represented as number of cells per million cytometric
events.
Statistical Analysis
Cell numbers are expressed as mean ± s.e.m per 106
events. Normal distribution of the data was confirmed
through Kolmogorov-Smirnov test. Skewed distribu-
tions were log transformed for statistical analysis.
Comparisons between two groups and within groups
were performed by the unpaired and paired Student’s
t test respectively for continuous variables. For non-
parametric variables, Mann-Whitney’s test and Wil-
coxon matched pair test were employed. Correlation
between cell counts and biochemical parameters were
assessed with Spearman’s Rank coefficient (r). Statisti-
cal significance was accepted if the null hypothesis
could be rejected at p < 0.05. All analyses were done
using Windows - based SPSS statistical software
(version15.0).
Results
Characteristics of the study population
The morphometric, clinical and metabolic features of
the study group are summarized in Table 1. None of
the subjects were on medication at the time of recruit-
ment and all provided written consent for the study.
The pre-diabetes group had significantly higher body
weight (p = 0.026), higher BMI (p = 0.005) and
increased waist circumference (p = 0.032). The WHR
was also higher for the pre-diabetes group though the
increase did not reach level of significance. Among the
glucose and insulin profiles, the pre-diabetes group had
higher levels of fasting glucose, fasting insulin, post load
glucose and post load insulin. Also the pre-diabetes
group had greater insulin resistance as measured by
HOMA-IR (p = 0.0001). The HbA1c levels were signifi-
cantly higher in pre-diabetes group compared to the
NGT group. There was a marginal increase in the neu-
trophil counts which was approaching significance while
the lymphocytes were decreased in the pre-diabetes
group (Table 2 p = 0.063). For the benefit of the readers
the clinical profiles of IFG and IGT subjects within the
pre-diabetes group are further listed in Table 3. As seen
in Table 3 the weight of IFG subjects was significantly
higher than NGT. Both the IFG and IGT subjects were
Table 1 Anthropometric, clinical and biochemical
characteristics of study subjects
Parameters NGT Pre-diabetes p value
(n = 24) (n = 26)
Anthropometric measures
Age (years) 36 ± 2 39 ± 2 0.232
Weight (Kg) 69 ± 2 77 ± 3* 0.026
Body Mass Index (kg/m2) 24.0 ± 0.6 26.5 ± 0.6* 0.005
Waist Circumference (cm) 90.3 ± 1.7 98.3 ± 3.1* 0.032
Waist - Hip Ratio 0.96 ± 0.01 0.98 ± 0.01 0.070
Systolic Blood Pressure (mmHg) 119.0 ± 1.8 122.8 ± 2.6 0.240
Diastolic Blood Pressure (mmHg) 76.3 ± 1.6 76.6 ± 1.9 0.992
Biochemical parameters
OGTT
Fasting plasma glucose (mmol/l) 5.0 ± 0.1 5.7 ± 0.1** 0.0001
2Hr Post plasma glucose (mmol/l) 5.6 ± 0.2 8.1 ± 0.3** 0.0001
Glycated Hemoglobin [HbA1c] (%) 5.4 ± 0.1 5.8 ± 0.1* 0.0013
Fasting Insulin (pmol/l) 49.8 ± 5 95.1 ± 10** 0.0002
2Hr post Insulin (pmol/l) 325.8 ± 49 780.0 ± 75** 0.0001
HOMA-IR 1.9 ± 0.2 4.0 ± 0.4** 0.0001
Lipid profile
Total Cholesterol (mmol/l) 4.6 ± 0.2 4.9 ± 0.2 0.376
Serum Triglycerides (mmol/l) 1.51 ± 0.2 1.9 ± 0.2 0.166
HDL Cholesterol (mmol/l) 1.0 ± 0.04 0.9 ± 0.04 0.459
LDL Cholesterol (mmol/l) 2.9 ± 0.1 3.0 ± 0.2 0.632
VLDL Cholesterol (mmol/l) 0.7 ± 0.1 0.9 ± 0.1 0.163
Others
Serum Creatinine (μmol/l) 79.6 ± 1.8 106.9 ± 27.1 0.364
Hs-CRP (mg/l) 2.5 ± 0.5 3.1 ± 0.5 0.341
Microalbuminuria (μg/mg) 5.2 ± 0.8 7.6 ± 1.5 0.344
Values are expressed as mean ± SEM. Hs - CRP indicates High sensitive
C - reactive protein. Glycated Hemoglobin values are expressed in %.*P < 0.05
and **P < 0.001.
Table 2 Hematology measurements of study subjects
Parameters NGT Pre-diabetes p value
(n = 24) (n = 26)
WBC count (109 /l) 6.8 ± 0.2 7.0 ± 0.3 0.717
Neutrophils (%) 51.5 ± 1.4 54.8 ± 1.6 0.076
Lymphocytes (%) 35.5 ± 1.3 32.3 ± 1.1 0.063
Monocytes (%) 8.1 ± 0.3 7.6 ± 0.3 0.148
Eosinophils (%) 4.7 ± 0.8 5.1 ± 0.7 0.727
Basophils (%) 0.18 ± 0.02 0.25 ± 0.04 0.177
RBC count (1012 /l) 5.1 ± 0.1 5.2 ± 0.1 0.750
Platelets (109 /l) 243.5 ± 7.7 247.8 ± 10.7 0.747
Values are expressed as mean ± SEM. Differential cell count values are
expressed in %.
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insulin resistant as measured via HOMA-IR and their
glucose and insulin profiles were accordingly higher
than the NGT group.
Circulating progenitor cells in NGT versus Pre-diabetes
group
Upon morphological gating of the lympho-monocyte
fraction based on forward and side scatter, the CD34+,
CD133+ and CD133+CD34+ cells were sorted following
gating with appropriate fluorophore labeled correspond-
ing isotype control antibodies (Figure 1). No differences
were observed in the fasting levels of CD34+ cells
between NGT and pre-diabetes subjects (1401 ± 417 vs
1751 ± 483, p = 0.589) or for CD133+ cells (34 ± 12 vs
52 ± 22, p = 0.874). Here the cell numbers are depicted
for every one million cytometric events counted. Simi-
larly no differences were seen in the circulation for fast-
ing levels of CD133+CD34+ cells between the two
groups (347 ± 114 vs 295 ± 69, p = 0.392 for NGT ver-
sus pre-diabetes respectively).
However at 2 hour post glucose load there was almost
a 3-fold increase in the CD34+ cell count in the NGT
group (p = 0.003) which appeared to be attenuated in
the pre-diabetes group with the p value approaching sig-
nificance (refer to Figure 2A, p = 0.066). No increase in
the CD133+ cells following glucose load was seen in
either of the study groups (data not shown). Similarly
a 2.5-fold increase was seen for CD133+CD34+ cells in
the NGT group (p = 0.019) at 2 hours following 75 g
glucose load, which was blocked in pre-diabetes group
(Figure 2B, p = 0.024).
Furthermore when the pre-diabetes group was further
split into IFG and IGT, the glucose mediated increase in
CD34+ and CD133+CD34+ was significantly blocked for
the IGT subjects (Figure 3). Intriguingly for the IFG
group there appeared to be an increase in the fasting
levels of CD34+ cells compared to NGT (Figure 3A) but
the p value did not reach significance (p = 0.133). With
regard to CD133+CD34+ cells the fasting levels of these
progenitor cells did not vary among the group though
the glucose-load induced increase appeared blunted for
IFG (Figure 3B). It should however be noted that these
observations are made with limited number of volun-
teers subjected to a restricted OGTT analysis which
scores cell numbers only at fasting and 2 hour post load
stages. This hence warrants for a detailed analysis of
progenitor cell kinetics every 30 minutes following
glucose challenge in future studies.
Correlation Analysis
Spearman’s Rank correlation analysis was performed to
determine correlation between progenitor cell numbers
and biochemical parameters. A positive correlation was
observed between CD34+ and CD133+CD34+ cells both
during fasting and 2 hour post glucose load. The Rho
value for fasting cell counts was 0.270 (p = 0.058) while
for 2 hour values the Rho between the two cell types
was 0.361 (p = 0.01). When fasting cell counts for CD34
+ were analyzed, no appreciable correlation was seen
with fasting profiles of glucose or insulin, however fast-
ing CD34+ cells showed a near significant inverse corre-
lation with cholesterol (r = -0.263, p = 0.064), LDL (r =
-0.259, p = 0.070) and serum creatinine (r = -0.249, p =
0.084). The fasting cell counts for CD133+CD34+ cells
exhibit a near significant and significant positive correla-
tion with fasting glucose (r = 0.245, p = 0.086) and post
load glucose (r = 0.297, p = 0.036) respectively. Serum
Table 3 Anthropometric, clinical and biochemical
characteristics of study subjects
Parameters NGT IFG IGT
(n = 24) (n = 09) (n = 17)
Anthropometric measures
Age (years) 36 ± 2 38 ± 2 40 ± 2
Weight (Kg) 69 ± 2 82 ± 4** 74 ± 3
Body Mass Index (kg/m2) 24.0 ± 0.6 27.0 ± 1.3* 26.2 ± 0.7*
Waist Circumference (cm) 90.3 ± 1.7 97.0 ± 2.2* 99.0 ± 4.7
Waist - Hip Ratio 0.96 ±
0.01
0.97 ± 0.01 0.98 ± 0.01
Systolic Blood Pressure
(mmHg)
119.0 ±
1.8
120.0 ± 1.9 124.3 ± 3.8
Diastolic Blood Pressure
(mmHg)
76.3 ± 1.6 75.6 ± 1.9 77.1 ± 2.7
OGTT
Fasting plasma glucose
(mmol/l)
5.0 ± 0.1 5.7 ± 0.1*** 5.7 ± 0.2***
2Hr Post plasma glucose
(mmol/l)
5.6 ± 0.2 6.8 ± 0.3** 8.8 ± 0.2***
##
Glycated Hemoglobin [HbA1c]
(%)
5.4 ± 0.1 5.6 ± 0.1 5.9 ± 0.1***
Fasting Insulin (pmol/l) 49.8 ± 5 93.7 ± 19 ** 95.8 ± 11***
2Hr post Insulin (pmol/l) 325.8 ±
49
653.1 ±
121**
1259 ±
231***
HOMA-IR 1.9 ± 0.2 3.9 ± 0.8*** 4.0 ± 0.5***
Lipid profile
Total Cholesterol (mmol/l) 4.6 ± 0.2 4.8 ± 0.4 4.9 ± 0.2
Serum Triglycerides (mmol/l) 1.51 ± 0.2 2.1 ± 0.4 1.8 ± 0.2
HDL Cholesterol (mmol/l) 1.0 ± 0.04 1.0 ± 0.09 1.0 ± 0.03
LDL Cholesterol (mmol/l) 2.9 ± 0.1 2.9 ± 0.3 3.1 ± 0.2
VLDL Cholesterol (mmol/l) 0.7 ± 0.1 0.9 ± 0.2 0.8 ± 0.1
Others
Serum Creatinine (μmol/l) 76.6 ± 2.3 73.7 ± 2.6 124.5 ± 41.2#
Hs-CRP (mg/l) 2.5 ± 0.5 2.0 ± 0.2 3.7 ± 0.6
Microalbuminuria (μg/mg) 5.2 ± 0.8 4.2 ± 0.6 9.4 ± 2.1
Values are expressed as mean ± SEM. Hs - CRP indicates High sensitive C -
reactive protein. Glycated Hemoglobin values are expressed in %. *P < 0.05,
**P < 0.001 &*** P < 0.0001 vs NGT and # P < 0.05 & ## P < 0.0001 vs IFG.
Nathan et al. BMC Endocrine Disorders 2011, 11:2
http://www.biomedcentral.com/1472-6823/11/2
Page 4 of 8
creatinine levels exhibited inverse correlation with post
glucose load cell counts of CD133+CD34+ cells (r =
-0.312, p = 0.023). Intriguingly the CD34+ cell counts
following glucose load demonstrated inverse correlation
with neutrophils, with r = - 0.330 (p = 0.019).
Discussion
In the current study, we report a 2 to 3-fold increase in
the circulating levels of CD34+ and CD133+CD34+ pro-
genitor cells in healthy Asian Indian males in response to
75 g glucose load. This increase in progenitor cell counts
is however attenuated in pre-diabetes subjects particu-
larly IGT. To the best of our knowledge this is the first
study to identify an increase in circulating progenitor
cells in response to glucose load in healthy individuals
and its attenuation in IGT. A positive correlation was
seen between CD34+ and CD133+CD34+ cells both at
fasting and post load stages, confirming a previous find-
ing that double positive cells are a subset of the CD34+
pool [19]. As previously reported we also observed an
inverse correlation of fasting CD34+ cell counts with cho-
lesterol and LDL [19], however the p values for these cor-
relations did not reach significance possibly due to small
sample size. Intriguingly the CD34+ cell counts following
glucose load showed inverse correlation with neutrophils
(p = 0.019). Additionally the post load CD133+CD34+
counts were inversely correlated with serum creatinine.
Progenitor cells besides giving rise to EPCs can inte-
grate into skeletal muscle, neurons or myo-endothelial
cells [1]. They exhibit better dispersion in host muscle
tissue following cryo injury and can form capillary like
structures [20]. Similarly CD133+CD34+ cells exhibit
a strong correlation with degree of engraftment in
multiple myeloma patients undergoing autologous
transplantation [21]. It is of interest that a recent study
also claims that HSC transplantation imparts insulin
independency in early type I diabetes patients [22].
Although the knowledge about mobilization of various
fractions of haematopoietic stem cells and the endogen-
ous processes governing physiological organ recoveries
mediated by them are scarce, it is tempting to speculate
that increases in circulating progenitor cell counts in
response to glucose load is possibly the body’s precau-
tionary response to protect various tissues and organs
from glycemic insults. In the likelihood of this possibility
the inverse correlation of CD133+CD34+ cells (r =
-0.312, p = 0.023) with serum creatinine is indeed inter-
esting. However these findings need to be tested and
characterized in experimental models of diabetes.
Unlike a recently published study by Fadini et.al.
[14], we did not observe any variations in the fasting
cell counts of CD34+ progenitor cells between the two
groups possibly due to small sample size. We however
observed an attenuated response at 2 hours post glu-
cose challenge for CD34+ and CD133+CD34+ cells in
the pre-diabetes group compared to the NGT group.
Although the mechanisms behind this blunted
response and the functional consequences of this aber-
ration are presently unknown it can be envisaged that
hostile vascular environment in pre-diabetes either due
to reactive oxygen species or inflammation may affect
the mobilization of progenitor cells from bone marrow.
It should be noted that pre-diabetes is associated with
increased oxidative stress and circulatory pro-inflam-
matory cytokines [15,23,24]. Given that the post glu-
cose load-cell counts for CD34+ inversely correlated
with neutophil counts, it is likely that decrease in pro-
genitor count is an effect of increased inflammatory
Figure 1 Representative FACS dot plot. Forward and side scatter of the peripheral blood samples depicting lymphocyte and monocyte
fraction for gating (A). Quadrant settings of the isotype control (B) and test sample (C) stained with their respective antibodies.
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state. Since we did not assess the oxidative stress in
these subjects, it is difficult at this stage to comment
on the influence of reactive oxygen species on mobili-
zation of progenitors from bone marrow in pre-dia-
betes subjects. Alternatively it is likely that reduction
in post load progenitor cell counts in pre-diabetes sub-
jects is due to accelerated progenitor cell senescence
which unfortunately was not investigated in this study.
Ageing is known to restrict the bone marrow reserve
of progenitor cells and reduce circulating numbers of
these cells [25,26]. Hence this study was performed
with age matched younger subjects. The other advan-
tage of this study is the recruitment of drug naïve
NGT and pre-diabetes subjects. Thus any compound-
ing effects of either medication or age are minimized
and the study provides a reasonable indication of
influence of glucose challenge on progenitor cell
count. It is likely that blunted post load response of
progenitor cells may precede the actual decrease seen
under fasting conditions for these cells during the
course of developing diabetes [7,10], thereby suggesting
that insults to vasculature and possibly other organs
occur prior to the onset of overt diabetes diagnosed
through fasting glucose levels [27]. Finally whether
similar progenitor dynamics with regard to post glu-
cose challenge is seen in other populations prior to or
during the onset of diabetes is currently unknown and
this points to need for replication of the findings in
other populations.
Limitations
There are certain limitations of the current study. For
example due to small sample size certain observations did
not reach levels of statistical significance. Similarly
although in the IFG subjects there appears to be an
increase in the fasting levels of CD34+ cells as opposed to
NGT, it fails to reach statistical significance. Additionally
due to small sample size we could not perform sub-group
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Figure 2 Circulating progenitor cells in study subjects
following glucose challenge. CD34+ cells (A) and CD133+CD34+
cells (B) represented per million cytometric events at fasting and
2 hour post glucose challenge (2Hr PLG). Bar graphs summarize
data as mean ± SEM; * p < 0.05 and ** p < 0.01 represents
statistical significance.
Figure 3 Circulating progenitor cells in NGT, IFG and IGT
subjects following glucose challenge. CD34+ cells (A) and CD133
+CD34+ cells (B) represented per million cytometric events at fasting
and 2 hour post glucose challenge (2Hr PLG). Bar graphs summarize
data as mean ± SEM; * p < 0.05 and ** p < 0.01 represents
statistical significance.
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analysis and being observational in nature, the causative
factors could not be determined. The other limitation of
the study is a restricted OGTT analysis with measurement
of glucose and insulin only at fasting and 2 hour post glu-
cose challenge. A detailed analysis every 30 minutes would
give a better perspective on progenitor cell kinetics as a
function of metabolic parameters. Finally the study
addresses the progenitor cell dynamics in Asian Indian
male subjects, whether similar dynamics are seen in female
subjects’ remains to be seen.
Conclusions
Glucose challenge increases circulating levels of CD34+
and CD133+CD34+ haematopoietic stem cells in healthy
subjects which is compromised in subjects with IGT.
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